Gadobutrol

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Gadobutrol
Gadobutrol skeletal.svg
Systematic (IUPAC) name
gadolinium(III) 2,2',2''-(10-((2R,3S)-1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate
Clinical data
AHFS/Drugs.com International Drug Names
Licence data US FDA:link
Pregnancy cat. C (US)
Legal status POM (UK) -only (US)
Routes IV
Identifiers
CAS number 138071-82-6 YesY
ATC code V08CA09
PubChem CID 72057
DrugBank DB06703
UNII 1BJ477IO2L YesY
KEGG D07420 YesY
ChEBI CHEBI:68841 N
ChEMBL CHEMBL1628503 N
Chemical data
Formula C18H31GdN4O9 
Mol. mass 604.710 g/mol
 N (what is this?)  (verify)

Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA).

It received marketing approval in Canada[1] and in the United States.[2][3][4]

As of 2007, it was the only GBCA approved at 1.0 molar concentrations.[5]

Gadobutrol is marketed by Bayer Schering Pharma as Gadovist, and by Bayer HealthCare Pharmaceuticals as Gadavist.[6]

References[edit]